Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839367 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29401385 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1486273 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL7391110 | 1.00 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL10028351 | 0.91 | KMT2A (0.53) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL13863441 | 0.91 | KMT2A (0.53) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL11949183 | 0.91 | CASP3 (0.47) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL377523 | 0.90 | MDM4 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL30564455 | 0.90 | MDM4 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29738269 | 0.90 | MDM4 (0.50) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005503-A | Ultrasonic response apoptosis bionic targeting nano-carrier delivery material and preparation method thereof | 暨南大学 | 2026-05-12 | — | — | CN | claimed |
| CN-119954987-A | Apoptosis bionic nano drug delivery carrier and preparation method and application thereof | 暨南大学 | 2025-05-09 | — | — | CN | claimed |
| CN-114315940-A | Preparation method of 2-deoxygalactoside | 华东师范大学 | 2022-04-12 | — | — | CN | claimed |
| CN-122005503-A | Ultrasonic response apoptosis bionic targeting nano-carrier delivery material and preparation method thereof | 暨南大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119954987-A | Apoptosis bionic nano drug delivery carrier and preparation method and application thereof | 暨南大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119504686-A | Human cystathionine gamma-lyase response fluorescent dye, and preparation method and application thereof | 大连理工大学宁波研究院 | 2025-02-25 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114315940-A | Preparation method of 2-deoxygalactoside | 华东师范大学 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | KMT2A 2905/4885CASP3 2464/4885MDM4 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.